Capricor Therapeutics has initiated legal action against its distribution partners to ensure that patients with Duchenne muscular dystrophy (DMD) can access a potentially life-changing cell therapy. The lawsuit centers on claims of inadequate launch preparations and a pricing structure that could render the treatment inaccessible to a vast majority of the patient population.
Capricor Therapeutics Files Lawsuit Over Deramiocel Launch
On May 7, 2026, Capricor Therapeutics (NASDAQ: CAPR) announced it has filed a lawsuit against Nippon Shinyaku Co., Ltd. And its U.S. Subsidiary, NS Pharma, Inc. The dispute involves the U.S. Distribution agreement for deramiocel, an investigational cell therapy designed to treat Duchenne muscular dystrophy.
According to the complaint, Capricor alleges that NS Pharma failed to adequately prepare for the commercial launch of the therapy. More critically, Capricor identifies a “fundamental pricing flaw” within the Commercialization and Distribution Agreement. The company argues that this specific pricing mechanism would prevent patients relying on private insurance, Medicare, or Medicaid from being able to afford or access the therapy.
Capricor stated that it attempted to resolve these pricing issues in good faith, but NS Pharma refused to compromise, leaving legal action as the only viable path to ensure the treatment reaches the patients who need it.
Understanding Duchenne Muscular Dystrophy and Deramiocel
Duchenne muscular dystrophy (DMD) is a fatal genetic disorder that primarily affects boys and young men. In the United States, approximately 15,000 people live with this condition. DMD leads to progressive muscle degeneration, which eventually impacts the ability to walk and breathe.
Deramiocel is an allogeneic cardiosphere-derived cell therapy currently in phase 3 clinical trials. Unlike some treatments that focus on a single aspect of the disease, deramiocel is designed to address both the skeletal and cardiac manifestations of DMD, making it a significant therapeutic advance in the field of rare diseases.
“I have spent nearly two decades building Capricor with one goal in mind: making Deramiocel available to treat these boys,” said Dr. Linda Marbán, CEO of Capricor.
What This Means for Patient Access
The primary objective of the lawsuit is to rescind the existing agreement with Nippon Shinyaku and NS Pharma. By breaking this partnership, Capricor aims to establish a new path to market that removes the pricing barriers currently hindering access for insured patients.
If the pricing flaws remain unaddressed, a significant portion of the 15,000 U.S. Patients could be locked out of the therapy due to insurance reimbursement failures or prohibitive out-of-pocket costs. Capricor’s legal strategy is focused on ensuring that the commercialization process prioritizes patient reach over restrictive contractual pricing structures.
Key Takeaways: The Capricor vs. NS Pharma Dispute
- The Conflict: Capricor is suing Nippon Shinyaku and NS Pharma over the U.S. Distribution of deramiocel.
- The Core Issue: A “fundamental pricing flaw” in the agreement may block access for patients on Medicaid, Medicare, and private insurance.
- The Therapy: Deramiocel is a cell therapy targeting both cardiac and skeletal muscle issues in DMD patients.
- The Goal: Capricor seeks to rescind the distribution agreement to ensure the therapy reaches the estimated 15,000 DMD patients in the U.S.
Frequently Asked Questions
What is deramiocel?
Deramiocel is an investigational allogeneic cardiosphere-derived cell therapy developed by Capricor Therapeutics for the treatment of Duchenne muscular dystrophy (DMD).
Why is Capricor suing its partner?
Capricor alleges that its partner, NS Pharma, failed to prepare for the commercial launch and insisted on a pricing structure that would make the drug inaccessible to patients with standard insurance coverage.
Who is affected by Duchenne muscular dystrophy (DMD)?
DMD is a fatal genetic disorder that affects approximately 15,000 people in the U.S., predominantly boys and young men.
Looking Ahead
The outcome of this legal battle will be pivotal for the DMD community. While deramiocel represents a major scientific breakthrough in treating both heart and skeletal muscle degeneration, its clinical value is moot if the commercial framework prevents it from reaching the bedside. The industry will be watching closely to see if Capricor can successfully decouple from its partner and implement a more patient-centric distribution model.